The Future of Progressive Multiple Sclerosis Therapies.

Autor:	Hollen CW; is Multiple Sclerosis Fellow and is a Neurologist and the Associate Director of Clinical Affairs for the MSCoE-West, both at the VA Portland Health Care System in Oregon. is a Neurologist and the Clinical Director of the MSCoE-West Regional Program at the VA Salt Lake City Health Care System in Utah. is a Neurologist and the Clinic Director of the MS Clinic at the Birmingham VA Medical Center in Alabama., Paz Soldán MM; is Multiple Sclerosis Fellow and is a Neurologist and the Associate Director of Clinical Affairs for the MSCoE-West, both at the VA Portland Health Care System in Oregon. is a Neurologist and the Clinical Director of the MSCoE-West Regional Program at the VA Salt Lake City Health Care System in Utah. is a Neurologist and the Clinic Director of the MS Clinic at the Birmingham VA Medical Center in Alabama., Rinker JR 2nd; is Multiple Sclerosis Fellow and is a Neurologist and the Associate Director of Clinical Affairs for the MSCoE-West, both at the VA Portland Health Care System in Oregon. is a Neurologist and the Clinical Director of the MSCoE-West Regional Program at the VA Salt Lake City Health Care System in Utah. is a Neurologist and the Clinic Director of the MS Clinic at the Birmingham VA Medical Center in Alabama., Spain RI; is Multiple Sclerosis Fellow and is a Neurologist and the Associate Director of Clinical Affairs for the MSCoE-West, both at the VA Portland Health Care System in Oregon. is a Neurologist and the Clinical Director of the MSCoE-West Regional Program at the VA Salt Lake City Health Care System in Utah. is a Neurologist and the Clinic Director of the MS Clinic at the Birmingham VA Medical Center in Alabama.
Jazyk:	angličtina
Zdroj:	Federal practitioner : for the health care professionals of the VA, DoD, and PHS [Fed Pract] 2020 Apr; Vol. 37 (Suppl 1), pp. S43-S49.
Abstrakt:	Introduction: Multiple sclerosis (MS) affects more than a million people in the US. A considerable portion of these patients either begin with primary progressive disease or eventually transition to secondary progressive MS. A progressive disease course is the most critical factor affecting disability accumulation. The relatively recent development of treatments for relapsing multiple sclerosis has had a profound impact on the disease course for many with MS. Unfortunately, therapies for progressive MS have not had the same degree of advancement in general. New insights into the pathophysiology of progressive MS may lead to new treatments. Observations: In this review, we identify some of the significant challenges encountered in the development of therapies for progressive MS, assess the evidence for use of currently approved therapies for patients with progressive MS, identify some of the current therapies in development from progressive MS, and consider the role for discontinuing therapy in certain patients. Conclusions: Developing effective disease modifying therapies that slow or stop the gradual accumulation of neurologic disability in progressive MS represents a critical unmet need. As the understanding of the inflammatory and neurodegenerative aspects of MS are better elucidated there may be opportunity for advancement in the treatment of progressive MS. Competing Interests: Author disclosures The authors report no actual or potential conflicts of interest with regard to this article. (Copyright © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu